礼来公司最新公布的临床试验结果为其新型减肥药Foundayo的安全性提供了有力支持，这项进展可能缓解市场对其安全性的担忧。该药物旨在与Wegovy制造商推出的同类产品展开竞争。
最新研究显示，对于患有2型糖尿病且心脏病风险较高的超重患者，Foundayo相较于常规疗法能够显著降低心脏病发作及其他心血管问题的风险。礼来同时强调，研究中未发现任何肝脏安全性警示信号。
这一发现具有重要意义——就在本周早些时候，美国食品药品监督管理局披露，其在4月1日批准Foundayo时，曾要求礼来进行额外测试以评估心血管事件和药物性肝损伤风险。此举曾引发市场担忧，认为安全性问题可能限制这款新药的市场潜力。值得注意的是，礼来的新药正与诺和诺德今年初推出的Wegovy减肥药展开激烈竞争。
受此利好消息影响，礼来公司股价出现温和上涨。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.